ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO032

Factors Influencing SGLT2i Utilization in an Inner-City Public Hospital

Session Information

Category: Diversity and Equity in Kidney Health

  • 900 Diversity and Equity in Kidney Health


  • Despradel, Luis C., New York City Health and Hospitals Jacobi, Bronx, New York, United States
  • Hti Lar Seng, Nang San, New York City Health and Hospitals Jacobi, Bronx, New York, United States
  • Jim, Belinda, New York City Health and Hospitals Jacobi, Bronx, New York, United States

Sodium-glucose cotransporter-2 inhibitors (SGLT2i’s) remained underutilized in chronic kidney disease (CKD) patients despite their renoprotective benefits. We present the factors associated with SGLT2i prescription in a public hospital in New York City.


Cross-sectional analysis of adult primary care patients at Jacobi Medical Center, Bronx, NY was done from Jan 2022 to Dec 2022. The sample included patients with CKD and Type 2 Diabetes Mellitus (T2DM). Exclusion criteria were no medication list and eGFR<20 mL/min/1.73 m2. Descriptive statistics and logistic regression analysis were performed using STATA 18 (StataCorp).


Among 2307 eligible patients, SGLT2i prescription rate was 14%. After controlling for gender, age, and subspecialty follow-up, no significant association was found between the prescription of SGLT2i and the patient's race, language, or coexisting comorbidities/complications. Please see Table 1 for the odds ratios of different significant variables.


Women were found to be prescribed less SGLT2i than men, perhaps due to side effects that affect women not identified in this study. Patients without insurance or with public insurance were more likely to be prescribed. As the drug can be dispensed in our hospital pharmacy for the uninsured as opposed to the need for an onerous prior authorization process for those with insurance; public insurances usually do not require prior authorization. Subspecialized services and hospital physicians increased the likelihood of SGLT2i prescription, perhaps reflecting the higher level of evidence-based application in a teaching hospital. By understanding these factors, we can strategize to enhance the utilization of this class of medications.

Table 1. Logistic Regression SGLT2i Prescription